Keywords: Bristol-Myers Squibb, Gilead Sciences, Reyataz, Cobicistat, HIV, Combination pill

Bristol-Myers in licensing deal with Gilead for combination HIV pill

Article | 26 October 2011

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a licensing accord with biotech firm Gilead Sciences (Nasdaq: GILD) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in